Expansion plans?

10/13/2014 10:16 AM ET
Alkermes plc (ALKS: Quote) has been declining for the majority of early trade Monday. The stock is now down 1.14 at $39.10.

Alkermes has been losing ground for the past 3 weeks and has dropped to nearly a 10-month low this morning.

The stock market has seen a huge correction the past few weeks idiot. What did you expect to happen?
 






Alkermes Plc (NASDAQ:ALKS) CFO James M. Frates sold 16,000 shares of Alkermes Plc stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $45.29, for a total value of $724,640.00. Following the completion of the transaction, the chief financial officer now directly owns 44,225 shares in the company, valued at approximately $2,002,950. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

You calling Mr. Frates, an idiot?
 












The stock market has seen a huge correction the past few weeks idiot. What did you expect to happen?

I'm sure this has nothing to do with the recent stock slipping moron. If you knew anything about the stock market you would know strong stocks with potential upside do not always follow the market up (or down). There are many many stock that have increased over the last few weeks in this slide.

I hate when people post on this site like they know what they are talking about but only have a fraction of knowledge about the topic they are trying to post.

https://www.pharmamedtechbi.com/~/m...eptember/Otsuka citizen petition 09_09_14.pdf
 
















































Alkermes Plc COO Sells $655,965 in Stock (ALKS)
Alkermes Plc (NASDAQ:ALKS) COO Gordon G. Pugh unloaded 14,577 shares of the company’s stock on the open market in a …
sleekmoney.com*· 4 hours ago
 






Is there any word on hiring of the DBL's for the possible launch? It is crickets out there. Did offers go out to internal candidates for the DBL positions? Please only answer if you are 100% certain.
 












SG&A spending shot up 31.5% from the year-ago quarter to $51.9 million. Costs associated with the marketing of Vivitrol and sales activity in anticipation of the potential launch of aripiprazole lauroxil (under FDA review for schizophrenia with a response expected by Aug 22, 2015) pushed up SG&A expenses.
 






Is there any word on hiring of the DBL's for the possible launch? It is crickets out there. Did offers go out to internal candidates for the DBL positions? Please only answer if you are 100% certain.

Ditto here. Have never experienced a more protracted process or lack of professionalism with the lack of follow up with candidates. Discouraging after a very positive initial experience.
 
























DBL offers Dec

Wouldn't it be nice if this company would tell the candidates that this is being put off till December? I have never experienced a more inappropriate handling in terms of lack of communication and follow up then this organization. You start interviewing in Sept, move on to F2F in October then hear nothing? Sad that Cafepharma is where I have to get an update. Thanks for posting this info.